Radiation Oncology Group
EORTC 22991 – Three Dimensional Conformal Radiotherapy / Intensity Modulated Radiotherapy alone vs Three Dimensional Conformal Radiotherapy / Intensity Modulated Radiotherapy plus adjuvant hormonal therapy in localized T1b-c, T2a, N0, M0 prostatic carcinoma.
A Phase III Randomized Study.
Thirty percent of patients with high-risk prostate cancer who undergo radiation biochemically, relapse within 5 years. Because prostate cancer is directly linked to androgens, androgen suppression is often another treatment for this disease. This EORTC study investigated whether adding 6 months of androgen suppression after radiation would improve disease-free survival in patients with high-risk prostate cancer. Results showed that, even after a 7 year follow up, radiotherapy plus androgen suppression significantly improved both biochemical and clinical disease-free survival compared to radiotherapy alone.